Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation and Depletion (2016 - 2025)

Editas Medicine (EDIT) has disclosed Depreciation and Depletion for 11 consecutive years, with $721000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion fell 54.91% to $721000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $5.8 million, a 0.85% decrease, with the full-year FY2024 number at $5.8 million, down 4.35% from a year prior.
  • Depreciation and Depletion was $721000.0 for Q3 2025 at Editas Medicine, down from $1.8 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.9 million in Q1 2025 to a low of $721000.0 in Q3 2025.
  • A 5-year average of $1.5 million and a median of $1.5 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 45.74% in 2021, then crashed 54.91% in 2025.
  • Editas Medicine's Depreciation and Depletion stood at $1.5 million in 2021, then rose by 1.92% to $1.5 million in 2022, then dropped by 4.81% to $1.5 million in 2023, then fell by 6.41% to $1.4 million in 2024, then crashed by 47.45% to $721000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Depreciation and Depletion are $721000.0 (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025).